Dimethyl fumarate for relapsing-remitting multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Dimethyl fumarate for relapsing-remitting multiple sclerosis.
For many years the only drugs licensed for the treatment of multiple sclerosis (MS) were administered by injection (interferon beta, glatiramer and ▼natalizumab). Recently, three oral drugs have become available. We have previously reviewed the use of ▼fingolimod for highly active relapsing-remitting MS1 and ▼teriflunomide for the management of relapsing-remitting MS in adults.2 Here, we review...
متن کاملP120: Efficacy and Safety of Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disorder of central nervous system. This demyelinating disease affects more than 2.3 million people world wild. Most of patients are young adult. The most common type of MS is relapsing remitting multiple sclerosis (RRMS). However there is no cure, available modifying therapies has revolutionized the care of patients with RRMS. Interferon (IFN) be...
متن کاملLiterature Highlight: Dimethyl Fumarate: an Investigational Drug for Relapsing/Remitting Multiple Sclerosis
Patients were 18-55 years old and were considered ambulatory (EDSS [Expanded Disability Status Scale] score ≤5). Patients were excluded if they had a progressive form of MS, another major disease, abnormal lab tests, or a recent exposure to contraindicated medication. The patients were randomly given either dimethyl fumarate 240 mg twice daily (BID), dimethyl fumarate 240 mg three times daily (...
متن کاملPharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
The last two decades have seen the introduction of several therapies for multiple sclerosis (MS). These therapies are intended to work at different levels of the disease, typically targeting direct symptom management, brief corticosteroid administration for acute exacerbations, and the regular use of disease-modifying drugs. Nevertheless, in clinical practice, disease-modifying drugs or immunos...
متن کاملDimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.
Multiple sclerosis (MS) shares an immune-mediated origin with psoriasis. Long-term safety and efficacy data generated in Europe from usage of fumaric acid formulations in the latter disease constituted grounds to investigate their effects in MS patients. Dimethyl fumarate (DMF) was found to be the active principle in those formulations and in vitro studies have demonstrated that DMF has immune-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Neurology
سال: 2014
ISSN: 1474-4422
DOI: 10.1016/s1474-4422(14)70159-0